hydroxyurea; hydroxycarbamide (Hydrea, Droxia)

From Aaushi
Jump to navigation Jump to search

Indications

Contraindications

Dosage

Capsules: 500 mg.

Pharmacokinetics

elimination via kidney

elimination via liver

1/2life = 2-4 hours

Adverse effects

Drug interactions

Test interactions

increases serum K+

Mechanism of action

More general terms

Additional terms

References

  1. Kaiser Permanente Northern California Regional Drug Formulary, 1998
  2. Drug Information & Medication Formulary, Veterans Affairs, Central California Health Care System, 1st ed., Ravnan et al eds, 1998
  3. Harrison's Principles of Internal Medicine, 14th ed. Fauci et al (eds), McGraw-Hill Inc. NY, 1998, pg 529, 533
  4. 4.0 4.1 4.2 FDA Medwatch http://www.fda.gov/medwatch/safety/2006/safety06.htm#Hydrea
  5. 5.0 5.1 5.2 5.3 5.4 Medical Knowledge Self Assessment Program (MKSAP) 16, 17. American College of Physicians, Philadelphia 2012, 2015
  6. Burns ER, Reed LJ, Wenz B. Volumetric erythrocyte macrocytosis induced by hydroxyurea. Am J Clin Pathol. 1986 Mar;85(3):337-41. PMID: https://www.ncbi.nlm.nih.gov/pubmed/3790210
  7. Platt OS. Hydroxyurea for the treatment of sickle cell anemia. N Engl J Med. 2008 Mar 27;358(13):1362-9. PMID: https://www.ncbi.nlm.nih.gov/pubmed/18367739
  8. Voskaridou E, Christoulas D, Bilalis A et al The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). Blood. 2010 Mar 25;115(12):2354-63. PMID: https://www.ncbi.nlm.nih.gov/pubmed/19903897
  9. 9.0 9.1 9.2 Stettler N et al. Proportion of adults with sickle cell anemia and pain crises receiving hydroxyurea. JAMA 2015 Apr 28; 313:1671 PMID: https://www.ncbi.nlm.nih.gov/pubmed/25919532
  10. Nevitt SJ et al Hydroxyurea (hydroxycarbamide) for sickle cell disease. Cochrane Database Syst Rev 2017 Apr 20; 4:CD002202 PMID: https://www.ncbi.nlm.nih.gov/pubmed/28426137 PMCID: PMC6478259 Free PMC article

Database